Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Nancy U Lin, Virginia Borges, Carey Anders, Rashmi K Murthy, Elisavet Paplomata, Erika Hamilton, Sara Hurvitz, Sherene Loi, Alicia Okines, Vandana Abramson, Philippe L Bedard, Mafalda Oliveira, Volkmar Mueller, Amelia Zelnak, Michael P DiGiovanna, Thomas Bachelot, A Jo Chien, Ruth O'Regan, Andrew Wardley, Alison Conlin Show all
Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2020
PURPOSE: In the HER2CLIMB study, patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer with brain metastases (BMs) showed statistically significant improvement in progression-free survival (PFS) with tucatinib. We describe exploratory analyses of intracranial efficacy and survival in participants with BMs. PATIENTS AND METHODS: Patients were randomly assigned 2:1 to tucatinib or placebo, in combination with trastuzumab and capecitabine. All patients underwent baseline brain magnetic resonance imaging; those with BMs were classified as active or stable. Efficacy analyses were performed by applying RECIST 1.1 criteria to CNS target lesions by investigator assessm..View full abstract
Supported by Seattle Genetics (Bothell, WA), the manufacturer of tucatinib, which also funded writing assistance in accordance with Good Publications Practice guidelines.